KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Asset Writedowns and Impairment (2016 - 2025)

Teladoc Health's Asset Writedowns and Impairment history spans 12 years, with the latest figure at $482000.0 for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 69.8% year-over-year to $482000.0; the TTM value through Dec 2025 reached $1000.0, down 99.97%, while the annual FY2025 figure was $1000.0, 99.97% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $482000.0 at Teladoc Health, up from -$858000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.6 million in Q1 2022 and bottomed at -$6.1 million in Q4 2022.
  • The 5-year median for Asset Writedowns and Impairment is $995000.0 (2022), against an average of $1.1 million.
  • The largest annual shift saw Asset Writedowns and Impairment skyrocketed 12630.0% in 2021 before it tumbled 706.93% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$750000.0 in 2021, then crashed by 706.93% to -$6.1 million in 2022, then skyrocketed by 95.89% to -$249000.0 in 2023, then soared by 740.96% to $1.6 million in 2024, then plummeted by 69.8% to $482000.0 in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Asset Writedowns and Impairment are $482000.0 (Q4 2025), -$858000.0 (Q3 2025), and $318000.0 (Q2 2025).